You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Hodgkin's Disease, Adult

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma Trial in New York (Isatuximab, Standard Procedures)

Recruiting
  • Lymphoma
  • +3 more
  • New York, New York
    Columbia University
Apr 27, 2022

Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Caba (Evaluation of

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • Evaluation of therapeutical approach after ASCT
  • Caba, Argentina
    FUNDALEU
Oct 1, 2021

Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

Active, not recruiting
  • Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +4 more
Apr 3, 2022

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Completed
Has Results
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +5 more
  • gemcitabine hydrochloride
  • bendamustine hydrochloride
  • Atlanta, Georgia
  • +1 more
Oct 21, 2021

Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma Trial in Tianjin (PD-1 inhibitor)

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • PD-1 inhibitor
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 14, 2021

Hodgkin Lymphoma, Adult Trial in Beijing (SHR-1210)

Completed
  • Hodgkin Lymphoma, Adult
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2021

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

Not yet recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • (no location specified)
Aug 4, 2023

Recurrent Adult Hodgkin Lymphoma Trial in Duarte (biological, drug, other, procedure)

Active, not recruiting
  • Recurrent Adult Hodgkin Lymphoma
  • basiliximab
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma Trial in Richmond (mycophenolate mofetil, Sargramostim, Filgrastim)

Active, not recruiting
  • Hodgkin's Lymphoma
  • +17 more
  • mycophenolate mofetil
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 21, 2021

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • UCD19 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT

Completed
  • Malignant Lymphoma
  • +3 more
    • (no location specified)
    Jul 8, 2020

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • ARI0003
    • Santiago De Compostela, A Coruña, Spain
    • +6 more
    Oct 24, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CD19 specific Chimeric Antigen Receptor T Cell
    • Columbus, Ohio
      Nationwide Children's Hospital
    Mar 9, 2023

    B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

    Recruiting
    • B Cell Non-Hodgkin's Lymphoma
    • CD19/CD20-directed CAR-T cells
    • Duarte, California
      City of Hope Medical Center
    Aug 10, 2022

    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

    Completed
    • Multiple Myeloma
    • +7 more
    • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Nov 2, 2022

    Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

    Recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Beijing, Beijing, China
      Han wei dong
    Jun 14, 2023